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Abstract
Introduction Characterizing and differentiating between
malignant tumors, benign tumors, and normal breast tissue is
increasingly important in the patient presenting with breast
problems. Near-infrared diffuse optical imaging and
spectroscopy is capable of measuring multiple physiologic
parameters of biological tissue systems and may have clinical
applications for assessing the development and progression of
neoplastic processes, including breast cancer. The currently
available application of near-infrared imaging technology for the
breast, however, is compromised by low spatial resolution,
tissue heterogeneity, and interpatient variation.
Materials and methods We tested a dynamic near-infrared
imaging schema for the characterization of suspicious breast
lesions identified on diagnostic clinical ultrasound. A portable
handheld near-infrared tissue imaging device (P-Scan; ViOptix
Inc., Fremont, CA, USA) was utilized. An external mechanical
compression force was applied to breast tissue. The tissue
oxygen saturation and hemoglobin concentration were recorded
simultaneously by the handheld near-infrared imaging device.
Twelve categories of dynamic tissue parameters were derived
based on real-time measurements of the tissue hemoglobin
concentration and the oxygen saturation.
Results Fifty suspicious breast lesions were evaluated in 48
patients. Statistical analyses were carried out on 36 out of 50
datasets that satisfied our inclusion criteria. Suspicious breast
lesions identified on diagnostic clinical ultrasound had lower
oxygenation and higher hemoglobin concentration than the
surrounding normal breast tissue. Furthermore, histopathologic-
proven malignant breast tumors had a lower differential
hemoglobin contrast (that is, the difference of hemoglobin
concentration variability between the suspicious breast lesion
and the normal breast parenchyma located remotely elsewhere
within the ipsilateral breast) as compared with histopathologic-
proven benign breast lesions.
Conclusion The proposed dynamic near-infrared imaging
schema has the potential to differentiate benign processes from
those of malignant breast tumors. Further development and
refinement of the dynamic imaging device and additional
subsequent clinical testing are necessary for optimizing the
accuracy of detection.
Introduction
Breast cancer remains the leading cause of newly diagnosed
cases of cancer among women in the United States, and the
second leading cause of cancer deaths [1]. In this regard, the
development and refinement of more innovative tools for ana-
lyzing the structural and physiologic characteristics of breast
tissue to more precisely characterize and differentiate malig-
nant tumors, benign tumors, and normal breast tissue
becomes increasingly important.
Current methods of breast screening have several limitations.
First, only approximately 20% of suspicious breast lesions
seen on mammography are ultimately proven malignant on
diagnostic breast biopsy [2]. Second, more dense breast
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tissue results in decreased sensitivity for detecting suspicious
lesions on mammography [3]. Third, considerable debate still
exists within the medical community with regards to the effec-
tiveness of clinical breast examination, as well as its lack of
performance consistency and standardization [4]. Fourth,
breast self-examination has not yet definitively been shown to
be associated with an overall reduction in breast cancer mor-
tality [5].
The most commonly used modalities for breast imaging are the
mammogram, ultrasound, and magnetic resonance imaging
[3]. These modalities primarily delineate the morphologic and
structural characteristics of breast tissue. Functional and
physiologic properties of the breast can be characterized by
such tools as dynamic contrast-enhanced magnetic reso-
nance imaging [6] and positron emission tomography [7].
These modalities for breast imaging, however, are not univer-
sally available and are highly cost prohibitive. In this regard, it
remains a priority to develop low-cost, portable, noninvasive
innovative imaging tools for structural and better functional
characterization of the breast.
Near-infrared (NIR) diffuse optical imaging and spectroscopy
is capable of measuring multiple physiologic parameters of
biological tissue systems and may have clinical applications
for assessing the development and progression of neoplastic
processes, including breast cancer [8-11]. In comparison with
traditional structural imaging modalities (that is, mammogram,
ultrasound, and magnetic resonance imaging), NIR imaging
reveals only functional properties of biological tissues without
anatomical characterization (that is, low spatial resolution).
Two major physiologic parameters measured by NIR imaging
and useful in the assessment of tumor-bearing tissues are tis-
sue blood oxygen saturation ([StO2]) and total hemoglobin
concentration ([Hbt]). Alterations in the local microvasculature
and the metabolism of developing malignant processes as
compared with the normal surrounding tissues may be detect-
able by NIR diffuse optical imaging and spectroscopy prior to
detection of any recognizable structural changes. For example,
malignant tissues may have lower oxygen saturation due to
imbalanced oxygen supply and uptake and increased blood
volume due to angiogenesis [12-14].
Furthermore, tumor hypoxia is a common characteristic of
locally advanced malignancies and has been shown to be
associated with a diminished therapeutic response and with
disease progression [15]. Tumor hypoxia results from an
imbalance between oxygen delivery and oxygen consumption
[16]. On the one hand, oxygen delivery is impaired by struc-
tural abnormalities present in the tumor microvasculature.
These structural abnormalities can result in numerous func-
tional impairments within the tumor microenvironment, includ-
ing capillary and vascular permeability [17], interstitial
hypertension [18], and increased flow resistance. On the
other hand, altered tumor cell metabolism, resulting in an ele-
vated metabolic rate, can also contribute to tumor hypoxia
[19]. The association of hypoxia with tumor development and
progression suggests that continuous monitoring of tumor
oxygenation and metabolism can play an important role in
assessing the development and progression of malignant
processes.
NIR has been used previously for measuring various breast tis-
sue characteristics, such as tissue absorbance, the scattering
coefficient, oxygen saturation, the hemoglobin concentration,
the lipid content, and the water content [20-26]. Measurable
differences between malignant breast lesions and normal
breast tissue for these particular breast tissue characteristics
can vary by as much as 75%, 23%, 50%, and 14%, respec-
tively [23]. Nevertheless, the menopausal status of the patient
can lead to significant intersubject variations in these breast
tissue characteristics by up to 200%, 16%, 180, and 50%,
respectively [22]. Furthermore, even for the same subject, spa-
tial variation in the location measured within the breast [24]
and the phase of the menstrual cycle [25] can produce signif-
icant variation in these breast tissue characteristics. These
breast tissue characteristics can vary by up to 16%, 1%, 14%,
and 5%, respectively, depending on the measurement position
[24], and can vary by up to 54%, 15%, 43%, and 64%,
respectively, depending on the phase of the menstrual cycle
[25]. These potentially large variations in tissue physiologic
properties seen in breast tissue imply that it is not appropriate
to use absolute values of these tissue parameters.
Investigators have therefore begun to examine various
dynamic imaging techniques for characterizing tissue proper-
ties [27-33]. The use of such dynamic imaging schemas intro-
duces external dynamics stimuli, such as physiologic stimuli,
chemical stimuli, or mechanical stimuli, to the biological tissue
system in order to allow one to measure relative changes in tis-
sue physiologic properties. By subtracting the tissue baseline
measurement from the dynamic response, the potential influ-
ence of tissue heterogeneity and interpatient variation can be
minimized.
We have previously developed and tested a handheld NIR
probe for dynamic imaging and characterization of biological
tissue systems in vivo [29,34]. In the current prospective clin-
ical trial, we have applied this technology to the evaluation of
suspicious breast lesions. This schema measures the relative
changes of tissue physical and physiologic properties in
response to an external compression stimulus. We hypothe-
size that the tumor oxygen dynamics in response to the exter-
nal stimulus may provide important information regarding
tissue viscoelasticity, metabolic demand, and vascular per-
fusion that may ultimately help to identify malignancy.Available online http://breast-cancer-research.com/content/9/6/R88
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Materials and methods
Equipment
As previously described [31,32,34], a mobile experimental
apparatus was developed that consists of a laptop computer,
a portable clinical ultrasound system (Terason 2000; Ter-
atech, Burlington, MA, USA), and a continuous wave-type,
portable NIR tissue imager (P-Scan; ViOptix Inc., Fremont, CA,
USA). The current system setup is shown in Figure 1. The port-
able clinical ultrasound system was used to locate the suspi-
cious breast lesion for appropriate positioning of the portable
NIR tissue imager. The NIR imager is a cuboid device measur-
ing 5.5 cm × 5.5 cm × 10.2 cm in dimensions. The imager has
a multilayer structure, consisting of a rigid aluminum outer
shell, a telescoping insert, and a black Delrin sensor head. Six-
teen light sources (eight sources for 690 nm and eight
sources for 830 nm) and eight detectors were placed in a 3
cm × 3 cm matrix on the black Delrin sensor head, as shown
in Figure 2. Light emission and detection were synchronized
by a PIC microprocessor with a 12-bit A/D. The compression
force was simultaneously measured by a miniature load cell
embedded inside the sensor head. The system acquired 66
measurements (32 measurements of light reflectance at each
wavelength and two measurements of compression force)
within 500 milliseconds, and reconstructed the two-dimen-
sional image of tissue oxygenation ([StO2]) and hemoglobin
concentration ([Hbt]) at a sampling rate of two frames per
second.
In the past, various NIR devices have been developed for
breast cancer detection [10]. These devices fall into three cat-
egories: continuous-wave devices, time-domain devices, and
frequency-domain devices. A continuous-wave device illumi-
nates the tissue with a steady or low-frequency light source.
The tissue absorption property is calculated based on the
attenuation of the reflectance intensity with the fixed input of a
reduced scattering coefficient or a differential path length fac-
tor [35,36]. A time-domain device detects tissue optical prop-
erties with depth resolution by sending short laser pulses of
femtoseconds to picoseconds into biological tissue and
recording the time-of-flight and the amplitude of photons
[37,38]. A frequency-domain device sinusoidally modulates at
a high frequency from 100 MHz to 1,000 MHz. By measuring
AC attenuation, DC attenuation, and the phase shift of the
resulting diffuse photon density wave, one can retrieve both
absorption and scattering properties of biological tissue with
accuracy and with resistance to ambient noises [39].
The device we utilized in the present clinical trial is a continu-
ous-wave device [34]. It differs from other continuous-wave
devices in that all the optoelectronic components are
integrated into a handheld unit without fiber optical connec-
tions. Another unique feature is that the device embeds a
Figure 1
System setup for the dynamic imaging system System setup for the dynamic imaging system. (a) System setup for 
dynamic imaging of suspicious breast lesions: the dynamic imaging 
system consists of a handheld near-infrared imager, a laptop computer, 
and a handheld ultrasound probe. (b) Close view of the handheld near-
infrared imager.
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Figure 2
Source and detector configurations on the surface of the P-Scan near- infrared imager (not to scale) Source and detector configurations on the surface of the P-Scan near-
infrared imager (not to scale). Sixteen sources and eight detectors are 
placed on the surface of the near-infrared imager, forming a 4 × 4 
matrix. The overall size of the probe matrix is 50.8 mm × 50.8 mm. (i, j), 
pixels at the intersection of the ith row and the jth column. Tissue blood 
oxygen saturation ([StO2]) and total hemoglobin concentration ([Hbt]) 
values were calculated at each pixel (i, j).
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compression load cell that enables the feedback control of the
compression load and the real-time monitoring of the pres-
sure-induced tissue optical property changes. Compared with
time-domain and frequency-domain devices, this device has
the advantages of low cost, simplicity, and real-time image-
processing capability. Owing to the limited number of wave-
lengths (690 nm and 830 nm) used in our device, however,
only oxyhemoglobin and deoxyhemoglobin concentrations are
detectable, assuming that these two chromophores are the
major sensitive chromophores in the NIR region. In contrast,
other researchers have used more wavelengths to retrieve
additional information regarding water, lipid concentrations,
and other chromophore concentrations [21,23].
Study design
The present trial was an unblinded, pilot study to test the clin-
ical feasibility of a dynamic NIR imaging device. The study pro-
tocol was approved by the Ohio State University
Comprehensive Cancer Center Scientific Review Committee
(Protocol Number OSU-04117) and by the Cancer Institu-
tional Review Board of the Arthur G. James Cancer Hospital
and Richard J. Solove Research Institute and Comprehensive
Cancer Center of Ohio State University (IRB number
2005C005).
Clinical data collection was performed at JamesCare (Dublin,
OH, USA), our comprehensive breast health services facility of
the Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute and Comprehensive Cancer Center of
Ohio State University. Patients were eligible to participate in
the study if they were 18 years of age or older, were not preg-
nant, and had a suspicious breast lesion (Breast Imaging
Reporting and Data System 4 or 5) that was identifiable on
ultrasound (either on both mammogram and ultrasound or on
ultrasound alone). Eligible patients were informed of the inves-
tigational nature of the study protocol and were required to
read, agree to, and sign a statement of informed consent prior
to participation.
The breast dynamic NIR imaging session for each eligible sub-
ject was arranged to take place immediately after a diagnostic
clinical ultrasound was performed, but prior to a scheduled
ultrasound-guided breast biopsy procedure. During the
dynamic NIR imaging session, each subject was placed in a
supine position, with her ipsilateral arm placed above her head
and her ipsilateral upper torso tilted slightly upward. First, the
Terason 2000 ultrasound probe was used to detect the loca-
tion and the shape of the suspicious lesion. Subsequently, the
P-Scan imager was then placed over the area of the suspi-
cious breast lesion for continuous data collection.
Each dynamic loading cycle lasted for a period of approxi-
mately 20 seconds, during which time a compression force
(up to a maximum of 15 N) was gradually applied to and
released from the breast tissue by the operator. The selection
of 15 N as the maximal compression force is in compliance
with Mammography Quality Standard Act regulation
900.12(e)(4). The 20-second compression frequency was
estimated by taking into account the device's sampling rate,
the operator's controllability, and the viscoelastic response of
the biological tissue. Each 20-second cycle consisted of a 10-
second baseline measurement, 5 seconds of gradual increas-
ing compression (compression phase), and 5 seconds of
gradually releasing compression (release phase). As the P-
Scan imager was compressed on and gradually released from
the breast tissue by the operator, the compression force was
recorded dynamically, as shown in Figure 3.
For each patient, such a dynamic compression profile was
generated for both the area of the suspicious breast lesion
(which includes the suspicious breast lesion itself that was
identified on ultrasound and the immediately adjacent sur-
rounding breast tissue) and the normal reference tissue (rep-
resenting normal breast parenchyma verified on diagnostic
clinical ultrasound and located remotely elsewhere within the
ipsilateral breast). This is schematically shown in Figure 4. An
ultrasound-guided breast biopsy was performed on each
patient after the initial dynamic NIR imaging session was
completed.
From March 2005 to August 2005, a total of 48 patients with
a suspicious breast lesion seen on ultrasound were recruited
into this prospective pilot clinical trial, of which two patients
had bilateral suspicious breast lesions. Data were therefore
collected on a total of 50 suspicious breast lesions with refer-
ence baseline measurements determined from normal breast
parenchyma located remotely elsewhere within the ipsilateral
breast. The average depth of the 50 suspicious breast lesions
from the skin surface was 1.15 cm (range, 0.36–2.66 cm;
Figure 3
Typical compression force profile detected during a single dynamic  loading cycle Typical compression force profile detected during a single dynamic 
loading cycle. A typical compression force profile detected during a 
single dynamic loading cycle when the operator compresses the P-
Scan device on breast tissue and gradually releases it. The compres-
sion profile was divided into three sections: baseline, compression, and 
releasing. Each test cycle started with a baseline measurement at a 
minor load of 2 N for about 10 seconds, followed by a ramped com-
pression load up to 15 N during 5 seconds, and ended with a gradual 
releasing of the compression load during 5 seconds.
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standard deviation, ± 0.50 cm). Of these 50 suspicious breast
lesions, 14 had a calculated cuboidal volume estimate (based
on the three dimensions of the lesion recorded on ultrasound)
of greater than 3.375 cm3 (approximating a three-dimensional
lesion size of 1.5 cm × 1.5 cm × 1.5 cm). These 14 suspicious
breast lesions were excluded from the data analysis based on
the following rationale: since the P-Scan imager has an active
detection area less than 3 cm × 3 cm, a lesion with a cross-
sectional area that is greater than 1.5 cm × 1.5 cm would
result in compromised contrast between the lesion and the
immediately adjacent surrounding breast tissue in two-dimen-
sional [StO2]/[Hbt] maps; and since the reference baseline
measurements were taken on normal breast parenchyma
located remotely elsewhere within the ipsilateral breast, a
lesion with a cross-sectional area that is greater than 1.5 cm ×
1.5 cm would increase the risk of interference between refer-
ence baseline measurements and lesion measurements. For
these reasons, we derived tissue parameters and performed
biostatistics analyses on 36 lesions only.
Tissue parameters
For each set of measurements, [StO2]i,j  and [Hbr]i,j  were
reconstructed at each pixel (i, j) in Figure 2, where i = 1–4 and
j = 1–4 [35]. The following tissue parameters were derived
based on dynamic measurements of tissue [StO2]i,j  and
[Hbr]i,j. Parameters 1–6 are applicable for both baseline meas-
urements and measurements at peak compression loads.
Parameter 1. Averaged tissue [StO2]:
This parameter was averaged over 16 pixels (4 × 4 matrix) of
a single detection window. The parameter was calculated both
at baseline (no compression) and at peak compression load.
Parameter 2. Averaged tissue [Hbt]:
This parameter was averaged over 16 pixels (4 × 4 matrix) of
a single detection window. The parameter was calculated both
at baseline (no compression) and at peak compression load.
Parameter 3. Relative [StO2] contrast:
This parameter calculated the standard deviation of [StO2] val-
ues in a 4 × 4 matrix. It was an indicator of [StO2] heterogene-
ity over the region of detection.
Parameter 4. Relative [Hbt] contrast:
This parameter calculated the standard deviation of [Hbt] val-
ues in a 4 × 4 matrix. It was an indicator of [Hbt] heterogeneity
over the region of detection.
Parameter 5. Differential [StO2]:
This parameter calculated the relative   difference
between the suspicious breast lesion (denoted 'T' for tumor)
and the normal breast parenchyma located remotely else-
where within the ipsilateral breast (denoted 'R' for reference).
Parameter 6. Differential [Hbt]:
This parameter calculated the   difference between the
suspicious breast lesion and the normal breast parenchyma
located remotely elsewhere within the ipsilateral breast.
Parameter 7. Differential [StO2] contrast:
D [StO2] = δ[StO2]q 
T - δ[StO2]q 
R q = B, P (7)
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Schematic depiction of the P-Scan breast imaging technique Schematic depiction of the P-Scan breast imaging technique. For each 
patient, a dynamic compression profile was generated for both the area 
of the suspicious breast lesion (which includes the suspicious breast 
lesion itself that was identified on ultrasound and the immediately adja-
cent surrounding breast tissue) and the normal reference tissue (repre-
senting normal breast parenchyma located remotely elsewhere within 
the ipsilateral breast).
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This parameter compared [StO2] heterogeneity between the
suspicious breast lesion and the normal breast parenchyma
located remotely elsewhere within the ipsilateral breast. ('B'
represents baseline measurements and 'P' represents meas-
urements at the peak compression load.)
Parameter 8. Differential [Hbt] contrast:
D [Hbt] = δ[Hbt]q 
T - δ[Hbt]q 
R q = B, P (8)
This parameter compared [Hbt] heterogeneity between the
suspicious breast lesion and the normal breast parenchyma
located remotely elsewhere within the ipsilateral breast.
Parameter 9. Variation in differential [StO2]:
This parameter evaluated how differential [StO2] changes in
response to compression force.
Parameter 10. Variation in differential [Hbt]:
This parameter evaluated how differential [Hbt] changes in
response to compression force.
Parameter 11. Differential variations of [StO2]:
DD [StO2] = Δ[StO2]T - Δ[StO2]R (11)
This parameter evaluated how the [StO2] values of the tumor
and the normal breast parenchyma located remotely else-
where within the ipsilateral breast respond differently to the
compression load.
Parameter 12. Differential variations of [Hbt]:
DD [Hbt] = Δ[Hbt]T - Δ[Hbt]R (12)
This parameter evaluated how the [Hbt] values of the tumor
and the normal breast parenchyma located remotely else-
where within the ipsilateral breast respond differently to the
compression load.
Statistical analyses
The software program SPSS 14.0 for Windows (SPSS, Inc.,
Chicago, IL, USA) was used for all statistical analyses. First,
the tissue parameters were analyzed by comparing all suspi-
cious breast lesions identified on ultrasound (designated
'tumor') versus all of the normal reference tissues (represent-
ing the normal breast parenchyma located remotely elsewhere
within the ipsilateral breast; designated 'reference'). Second,
the tissue parameters were then analyzed by comparing all his-
topathologic-proven benign lesions (designated 'benign') ver-
sus all histopathologic-proven malignant lesions (designated
'malignant').
Since the ramped compression profile introduced coupled,
transient reactions in tissue structure and tissue [StO2]/[Hbt],
we analyzed only the baseline measurements and measure-
ments at the peak compression load. Since none of the data
deviated from normality using the Kolmogorov Smirnov test,
we compared 'tumor' versus 'reference tissue' using paired t
tests and we compared 'benign' versus 'malignant' using
unpaired t tests. A paired t test was used for the 'tumor' versus
'reference tissue' comparisons since, in each instance, these
represented paired observations that were collected from the
same patient. An unpaired t test (two-independent-sample t
test) was used for the 'benign' versus 'malignant' comparisons
since these represented two independent groups of unequal
sample sizes. Since a large number of different comparisons
of the multiple tissue parameters were analyzed, only resulting
P < 0.01 values were considered statistically significant.
Results
A total of 36 out of 50 suspicious breast lesions had a calcu-
lated cuboidal volume estimate ≤ 3.375 cm3  and were
included in the current analyses. Of these 36 suspicious
breast lesions, 22 showed benign histopathology (designated
'benign') and 14 showed malignant histopathology
(designated 'malignant'). Table 1 presents the histopathology
for these 36 suspicious breast lesions.
Table 2 presents the paired t-test results for all 36 suspicious
breast lesions ('tumor') versus their normal reference tissue
('reference'). First, 'tumor' differed from 'reference' in the aver-
aged [StO2] for both the baseline measurement (P < 0.001)
and the compression peak measurement (P < 0.001). Sec-
ond, 'tumor' differed from 'reference' in their averaged [Hbt] for
both the baseline measurement (P < 0.001) and the compres-
sion peak measurement (P < 0.001). Third, 'tumor' differed
from 'reference' by the relative [StO2] contrast at the
Δ[] [] [] SO SO SO tt B t P 22 2 =− (9)
Δ[] [][] Hbt Hbt Hbt BP =− (10)
Table 1
Histopathology findings for the 36 suspicious breast lesions
Lesion Histopathology findings n
Benign tumors (n = 22) Fibroadenoma 10
Fibrocystic changes 4
Ruptured cyst and fat necrosis 4
Intraductal papilloma 3
Sclerosing adenosis 1
Malignant tumors (n = 14) Invasive ductal carcinoma 12
Medullary carcinoma 1
Intracystic papillary carcinoma 1Available online http://breast-cancer-research.com/content/9/6/R88
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compression peak (P = 0.01). In this regard, 'tumor' showed
larger [StO2] contrast than 'reference', indicating a larger het-
erogeneity in oxygen distribution for suspicious breast lesions
versus normal reference tissues.
Despite these differences in tissue [StO2] and [Hbt] for suspi-
cious breast lesions (including both 'benign' tumors and
'malignant' tumors) and for their normal reference tissue, it
remains very difficult to derive generalized criteria that are
applicable for distinguishing 'benign' versus 'malignant'. This
difficulty, best exemplified in Figures 5 and 6, is clearly due to
tissue heterogeneity and interpatient variations. Figure 5 plots
the averaged [StO2] for all 'benign' tumors, 'malignant' tumors,
and their normal reference tissue. Figure 6 plots the averaged
[Hbt] for all 'benign' tumors, 'malignant' tumors, and their nor-
mal reference tissue. From these plots, it is generally very dif-
ficult to differentiate specific tissue types based on the
averaged [StO2] versus the averaged [Hbt]. As is shown in
Figure 7, however, if differential [StO2] and differential [Hbt]
values are plotted for each individual suspicious breast lesion
(including both 'benign' and 'malignant'), most of the
datapoints localize within the same quadrant. This indicates
that any given suspicious breast lesion ('tumor') tends to dis-
play a lower oxygenation and a higher hemoglobin concentra-
tion as compared with its surrounding normal reference tissue.
Table 3 summarizes the unpaired t-test comparisons for multi-
ple features (including patient age, tumor volume, and numer-
ous tissue parameter comparisons) derived from the 22
'benign' tumors and the 14 'malignant' tumors. 'Benign' tumors
and 'malignant' tumors differed from one another by age, dif-
ferential [Hbt] contrast at baseline, and differential [Hbt] con-
trast at compression peak (P = 0.006, P = 0.008 and P =
0.004, respectively). While 'benign' tumors were found in
younger patients, displayed higher differential [Hbt] contrast at
baseline, and displayed higher differential [Hbt] contrast at
compression peak, 'malignant' tumors were found in older
patients, displayed lower differential [Hbt] contrast at baseline,
Table 2
Paired t-test results comparing tissue parameters for the 36 suspicious breast lesions ('tumor') versus normal breast parenchyma 
within the ipsilateral breast ('reference')
Tissue parameter Tissue type Mean ± standard deviation P value
Averaged [StO2] – baseline (%) Tumor/reference 88.7 ± 8.9/92.8 ± 5.7 <0.001
Averaged [Hbt] – baseline (μM) Tumor/reference 11.0 ± 6.0/9.0 ± 5.0 <0.001
Relative [StO2] contrast – baseline (%) Tumor/reference 3.6 ± 3.7/2.3 ± 1.1 0.03
Relative [Hbt] contrast – baseline (%) Tumor/reference 15.3 ± 8.8/12.8 ± 7.0 0.04
Averaged [StO2] – compression peak (%) Tumor/reference 87.7 ± 10.0/91.7 ± 7.1 <0.001
Averaged [Hbt] – compression peak (μM) Tumor/reference 10.0 ± 6.0/8.0 ± 4.0 <0.001
Relative [StO2] contrast – compression peak (%) Tumor/reference 4.0 ± 3.7/2.8 ± 1.7 0.01
Relative [Hbt] contrast – compression peak (%) Tumor/reference 15.5 ± 9.8/13.9 ± 10.0 0.2
Variation in differential [StO2] (%) Tumor/reference -0.5 ± 1.7/-0.4 ± 0.9 0.96
Variation in differential [Hbt] (%) Tumor/reference -0.2 ± 4.6/-1.2 ± 4.6 0.23
[Hbt], total hemoglobin concentration; [StO2], tissue blood oxygen saturation.
Significant P values are italicized.
Figure 5
Averaged tissue blood oxygen saturation measurements for benign  tumors, malignant tumors, and normal reference tissues Averaged tissue blood oxygen saturation measurements for benign 
tumors, malignant tumors, and normal reference tissues. x axis, number 
of patients; y axis, averaged tissue blood oxygen saturation ([StO2]) 
measurements. Pink bars, [StO2] measurements on the suspicious 
breast lesions (tumor); blue bars, [StO2] measurements on the normal 
surrounding breast parenchyma (reference). Patients 1–22 were diag-
nosed with benign tumors (patients 1 and 2, atypical intraductal papil-
loma; patients 3–5, fibrocystic changes; patient 6, fibrocystic changes 
with radial scar; patients 7–15, fibroadenoma; patient 16, fibroade-
noma with lactational change; patient 17, intraductal papilloma; 
patients 18–21, ruptured cyst and fat necrosis; and patient 22, scleros-
ing adenosis). Patients 23–36 were diagnosed with malignant tumors 
(patient 23, intracystic papillary carcinoma; patient 24–35, invasive 
ductual carcinoma; and patient 36, medullary carcinoma). For each 
patient, averaged [StO2] values were calculated on both the tumor tis-
sue and the reference tissue based on [StO2] measurements by the P-
Scan probe.
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and displayed lower differential [Hbt] contrast at compression
peak. Furthermore, mechanical compression further enhanced
the differences between 'benign' tumors and 'malignant'
tumors for differential [Hbt] contrast.
Discussion
Solid tumors are generally associated with reduced oxygen
saturation (due to hypoxia) [14-16,19] and with increased
hemoglobin concentration (due to unregulated angiogenesis)
[12,17,18]. NIR diffuse optical imaging and spectroscopy has
been used for noninvasive characterization of tumor-induced
tissue parameter changes [10]. Previous researchers have
demonstrated that breast tumors (both breast cancer and
fibroadenoma) typically show relatively lower oxygen satura-
tion and higher hemoglobin concentration in comparison with
those of reference breast tissues [9,23,40-42]. The pilot clini-
cal trial reported in the present manuscript demonstrated con-
sistent results in comparison with findings reported by
previous researchers.
Despite the observed differences between tumor and normal
tissue in terms of hemoglobin concentration and oxygen satu-
ration, clinical application of NIR technology into the arena of
breast cancer detection has not yet been realized. One of the
major obstacles is the difficulty to derive generalized criteria
for characterizing tissue differences that would ultimately allow
one to distinguish 'benign' findings versus 'malignant' tumors
within the breast. The difficulty comes from the significant
tissue heterogeneities and interpatient variations that may
exceed the characteristic difference between benign and
malignant tumors [22-25]. To overcome this difficulty, some
investigators studied tissue dynamic characteristics in
response to physiologic, chemical, and mechanical stimuli
[27-30,32]. Other investigators derived relative diagnostic cri-
teria by calculating differential oxygen and hemoglobin param-
eters between the tumor and the reference tissue in the
contralateral, cancer-free breast [20].
To minimize the influence of tissue heterogeneity and the inter-
patient variation, we developed a dynamic breast imaging
schema. By defining relative tissue parameters and studying
pressure-induced changes in these parameters, we hope to
derive more effective detection criteria that are less sensitive
to tissue heterogeneities and interpatient variations. Although
some tissue parameters defined in this paper are not yet fully
utilized due to the instrumentation limitations, the dynamic
imaging concept discussed in the present paper paves the
way for a low-cost, portable, reproducible imaging method for
breast cancer detection.
The results of the current prospective pilot clinical trial con-
firmed the clinical potential of the currently evaluated dynamic
NIR imaging schema. Statistically significant differences were
observed between 'tumor' and its surrounding normal refer-
ence tissue for averaged [StO2] and [Hbt] levels. Generally
Figure 6
Averaged total hemoglobin concentration measurements for benign  tumors, malignant tumors, and their normal reference tissues Averaged total hemoglobin concentration measurements for benign 
tumors, malignant tumors, and their normal reference tissues. x axis, 
number of patients; y axis, averaged total hemoglobin concentration 
([Hbt]) measurements. Pink bars, [Hbt] measurements on the suspi-
cious breast lesions (tumor); blue bars, [Hbt] measurements on the nor-
mal surrounding breast parenchyma (reference). Patients 1–22 were 
diagnosed with benign tumors (patients 1 and 2, intraductal papilloma 
with mild atypia; patients 3–5, fibrocystic changes; patient 6, fibro-
cystic changes with radial scar; patients 7–15, fibroadenoma; patient 
16, fibroadenoma with lactational change; patient 17, intraductal papil-
loma; patients 18–21, ruptured cyst and fat necrosis; and patient 22, 
sclerosing adenosis). Patients 23–36 were diagnosed with malignant 
tumors (patient 23, intracystic papillary carcinoma; patients 24–35, 
invasive ductual carcinoma; and patient 36, medullary carcinoma). For 
each patient, averaged [Hbt] values were calculated on both the tumor 
tissue and the reference tissue based on [Hbt] measurements by the P-
Scan probe.
Figure 7
Differential tissue blood oxygen saturation and total hemoglobin con- centration measurements for benign and malignant tumors Differential tissue blood oxygen saturation and total hemoglobin con-
centration measurements for benign and malignant tumors. Plot based 
on the dataset shown in Figures 4 and 5. x axis, differential tissue blood 
oxygen saturation ([StO2]) determined by subtracting the [StO2] meas-
urement of the suspicious breast lesion (tumor) from that of the normal 
surrounding breast parenchyma (reference); y axis, differential total 
hemoglobin concentration ([Hbt]) determined by subtracting the [Hbt] 
measurement of the suspicious breast lesion (tumor) from that of the 
normal surrounding breast parenchyma (reference).
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Table 3
Unpaired t-test results comparing multiple features (including patient age, tumor volume, and numerous tissue parameter 
comparisons) for the 22 'benign' tumors and the 14 'malignant' tumors
Parameter Tissue type Mean ± standard deviation P value
Age (years) Benign/malignant 44.0 ± 13.9/57.6 ± 13.6 0.006
Tumor volume (cm3) Benign/malignant 1.0 ± 0.9/1.4 ± 0.7 0.13
Tumor tissue [StO2] – baseline (%) Benign/malignant 87.9 ± 10.1/89.9 ± 6.8 0.51
Tumor tissue [Hbt] – baseline (μM) Benign/malignant 11.0 ± 6.0/11.0 ± 7.0 0.77
Reference tissue [StO2] – baseline (%) Benign/malignant 92.4 ± 5.3/93.5 ± 6.5 0.57
Reference tissue [Hbt] – baseline (μM) Benign/malignant 8.0 ± 4.0/9.0 ± 5.0 0.74
Differential [StO2] – baseline (%) Benign/malignant -6.1 ± 10.0/-4.1 ± 3.3 0.47
Differential [Hbt] – baseline (%) Benign/malignant 12.1 ± 32.3/17.8 ± 19.7 0.56
Tumor [StO2] contrast – baseline (%) Benign/malignant 4.1 ± 4.6/2.8 ± 1.2 0.34
Tumor [Hbt] contrast – baseline (%) Benign/malignant 16.6 ± 8.1/13.2 ± 9.7 0.27
Reference tissue [StO2] contrast – baseline (%) Benign/malignant 2.3 ± 1.1/2.3 ± 1.2 0.88
Reference tissue [Hbt] contrast – baseline (%) Benign/malignant 11.7 ± 5.6/14.4 ± 8.7 0.27
Differential [StO2] contrast – baseline (%) Benign/malignant 1.7 ± 4.1/0.5 ± 1.4 0.32
Differential [Hbt] contrast – baseline (%) Benign/malignant 4.8 ± 6.3/-1.2 ± 6.2 0.008
Tumor tissue [StO2] – compression peak (%) Benign/malignant 87.2 ± 11.4/88.6 ± 7.8 0.7
Tumor tissue [Hbt] – compression peak (μM) Benign/malignant 10.0 ± 6.0/11.0 ± 7.0 0.58
Reference tissue [StO2] – compression peak (%) Benign/malignant 91.4 ± 6.9/92.2 ± 7.6 0.76
Reference tissue [Hbt] – compression peak (μM) Benign/malignant 7.0 ± 4.0/8.0 ± 5.0 0.62
Differential [StO2] – compression peak (%) Benign/malignant -6.2 ± 12.8/-4.2 ± 4.7 0.59
Differential [Hbt] – compression peak (%) Benign/malignant 13.0 ± 33.7/22.6 ± 22.1 0.35
Tumor [StO2] contrast – compression peak (%) Benign/malignant 4.3 ± 4.2/3.6 ± 2.8 0.56
Tumor [Hbt] contrast – compression peak (%) Benign/malignant 16.4 ± 7.9/14.0 ± 12.5 0.48
Reference [StO2] contrast – compression peak (%) Benign/malignant 2.8 ± 1.4/2.8 ± 2.2 0.97
Reference [Hbt] contrast – compression peak (%) Benign/malignant 12.2 ± 6.1/16.7 ± 13.9 0.18
Differential [StO2] contrast – compression peak (%) Benign/malignant 1.6 ± 3.4/0.8 ± 1.7 0.45
Differential [Hbt] contrast – compression peak (%) Benign/malignant 4.3 ± 6.3/-2.7 ± 6.8 0.004
Variation in differential [StO2] (%) Benign/malignant 0.1 ± 4.5/0.2 ± 2.1 0.96
Variation in differential [Hbt] (%) Benign/malignant -0.9 ± 12.0/-4.9 ± 8.3 0.29
Variation in differential [StO2] – tumor (%) Benign/malignant -0.3 ± 1.4/-0.8 ± 2.1 0.41
Variation in differential [Hbt] – tumor (%) Benign/malignant 0.2 ± 4.2/-0.8 ± 5.2 0.54
Variation in differential [StO2] – reference (%) Benign/malignant -0.4 ± 0.6/-0.5 ± 1.3 0.79
Variation in differential [Hbt] – reference (%) Benign/malignant -0.4 ± 3.5/-2.3 ± 5.9 0.24
Differential variations of [StO2] – compression peak (%) Benign/malignant 0.1 ± 1.7/-0.3 ± 1.2 0.44
Differential variations of [Hbt] – compression peak (%) Benign/malignant 0.6 ± 4.7/1.5 ± 4.4 0.57
[Hbt], total hemoglobin concentration; [StO2], tissue blood oxygen saturation.
Significant P values are italicized.Breast Cancer Research    Vol 9 No 6    Xu et al.
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speaking, 'tumor' shows higher [Hbt] (probably due to angio-
genesis) and lower [StO2] (probably due to hypoxia) than the
normal surrounding breast parenchyma. Likewise, among all
'tumors', differences between 'benign' tumors and 'malignant'
tumors were demonstrated in terms of differential hemoglobin
contrast, indicating that 'benign' lesions display higher hetero-
geneity in terms of hemoglobin concentration than do 'malig-
nant' lesions. No difference was observed, however, between
'benign' lesions and 'malignant' lesions in terms of other tissue
parameters, such as averaged [StO2] and [StO2] contrast.
From the results of the current prospective pilot clinical trial, it
is evident that several technical limitations exist. Such limita-
tions of the currently evaluated dynamic NIR imaging schema
will need to ultimately be overcome in order to create a more
clinically relevant imaging schema.
The first technical issue of the current prospective pilot clinical
trial relates to the use of ramped compression (that is, gradual
increase or decrease of the compression load). Such a
ramped compression profile may not be the most ideal
mechanism for providing the dynamic stimulus. During ramped
compression, hemodynamic changes are intrinsically coupled
with tissue viscoelastic deformation that is induced by the
action of ramped compression. This makes the resultant quan-
titative analysis of such events quite difficult. For this particular
reason, and as previously mentioned in Materials and meth-
ods, our statistical analyses only considered two datapoints of
each dynamic loading cycle (that is, the baseline measurement
and the compression peak measurement). Additionally, the 5-
second ramped compression load used in this protocol was
not sufficient to result in significant tissue oxygenation
changes, as would be observed during tissue ischemia sec-
ondary to vascular occlusion. In our protocol, therefore, the
[StO2] fluctuations measured during compression were not
the result of tissue ischemia, but were instead the result of
additional tissue heterogeneity induced by relative changes in
the position of a given suspicious breast lesion and its adja-
cent normal reference tissue.
We propose two potential solutions to resolve these issues
with ramped compression. First, we can separate tissue defor-
mation from tissue physiologic changes by simultaneous
structural and functional imaging using an integrated NIR and
ultrasound imaging system. Second, we can replace the
ramped compression profile with a stepped compression pro-
file (that is, sudden increase or decrease of the compression
load). Such a stepped compression profile would uncouple
the tissue mechanical reaction (that is, transient tissue defor-
mation) from the physiologic reaction (that is, tissue ischemia).
As the result of using an integrated imaging system and a
stepped compression profile, we expect to see characteristic
differences in other tissue parameters that will ultimately help
to better differentiate 'malignant' from 'benign' lesions.
The second technical issue of the current prospective pilot
clinical trial relates to the instrumentation of the NIR imaging
system utilized. In general, NIR imaging systems fall into three
technical platforms, based on differences in the time depend-
ence of the excitation source intensity and the detection mech-
anism [10]. These technical platforms include continuous-
wave devices, time-domain devices, and frequency-domain
devices [10].
In the current prospective pilot clinical trial, we utilized a con-
tinuous wave NIR system (that is, the P-Scan imager). The
intrinsic limitation of such a continuous-wave system is that the
scattering coefficient cannot be explicitly resolved, and there-
fore differential path length factors or reduced scattering coef-
ficients have to be assumed [43]. In our current prospective
pilot clinical trial, constant reduced scattering coefficients
were used (  = 5/cm,   = 4/cm). The mismatch
between the assumed scattering coefficient and the actual
scattering coefficient can introduce measurement bias in
[StO2] and [Hbt]. In our current prospective pilot clinical trial,
a relatively higher [StO2] and a relatively lower [Hbt] were
observed as compared with [StO2] and [Hbt] measurements
recorded by other NIR imaging systems, such as a frequency
domain device [40]. Despite the above measurement bias, the
use of a continuous-wave device may still preserve its clinical
applicability secondary to its simplistic design and its low cost.
Furthermore, in our continuous-wave dynamic NIR imaging
schema, we derived only relative, differential tissue parameters
based on [StO2] and [Hbt] measurements, regardless of their
resultant bias in absolute values. In this regard, the influence
of the scattering coefficient mismatch would be further
reduced.
A final technical issue regarding the instrumentation of the NIR
imaging system utilized in the current prospective pilot clinical
trial is related to the limited image resolution. This limited
image resolution is the result of an insufficient number of
source-detector pixel positions for optical measurements and
the poor coregistration between sequential NIR and ultra-
sound imaging. The intrinsic problem of our limited imaging
resolution is related to high scattering and exponential attenu-
ation of light in biological tissues. To improve upon the limited
imaging resolution of our current NIR imaging system instru-
mentation, we plan to implement a step-motorized scanning
mechanism to increase the number of optical measurement
positions. Additionally, we plan to utilize an integrated NIR and
ultrasound imaging system for simultaneous image acquisition
during each dynamic loading cycle in order to monitor tumor
deformation and changes in tumor depth. We believe the
implementation of such an integrated system will allow us to
more precisely characterize specific differences between
benign and malignant breast lesions.
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Conclusion
The current prospective pilot clinical trial – utilizing a dynamic
NIR imaging device for characterizing breast tissue differ-
ences – demonstrated that suspicious breast lesions ('tumor')
had a lower [StO2] and a higher [Hbt] than its normal reference
tissues ('reference'), and that 'benign' lesions can be
distinguished from 'malignant' lesions based on differential
[Hbt] contrast. Although further technology development and
additional clinical testing are necessary to improve the detec-
tion sensitivity and specificity, the present prospective pilot
clinical trial demonstrates the potential of such a dynamic NIR
imaging device for identifying breast tissue differences that
may ultimately be useful as a noninvasive modality for distin-
guishing benign processes from those of breast cancer.
Competing interests
The P-Scan imager used for the clinical trial is a precommer-
cial prototype of ViOptix Inc. RXX, SPP, and DCY have no
competing interests. JJM is an employee of ViOptix, Inc.
Authors' contributions
RXX was the principle investigator responsible for the dynamic
NIR imaging system development, for clinical data collection,
and for data analyses. SPP was the clinical investigator super-
vising patient recruitment and data collection. DCY performed
all biostatistical analyses. JJM provided engineering support
for the P-Scan imager and helped to prepare the clinical pro-
tocol. RXX and SPP were responsible for writing and editing
all portions of the manuscript. All the authors read and
approved the final version of the manuscript.
Acknowledgements
The authors greatly appreciate the contributions of the following techni-
cal and clinical personnel: Bo Qiang, Abdul Rana, Lisa Yee, John Olsen, 
Jo Clarke, Janell Tucker, Lori Creiglow, and Maria Sanchez. They also 
appreciate the assistance and support of all the staff at JamesCare in 
Dublin during the clinical trial. This ongoing research effort was sup-
ported by an industrial contract (GRT00001204) and by Coulter Foun-
dation ECTR Award (RT00006454).
References
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer sta-
tistics, 2007.  CA Cancer J Clin 2007, 57:43-66.
2. Mendez A, Cabanillas F, Echenique M, Malekshamran K, Perez I,
Ramos E: Mammographic features and correlation with biopsy
findings using 11-gauge stereotactic vacuum-assisted breast
biopsy (SVABB).  Ann Oncol 2004, 15:450-454.
3. Mincey BA, Perez EA: Advances in screening, diagnosis, and
treatment of breast cancer.  Mayo Clin Proc 2004, 79:810-816.
4. McDonald S, Saslow D, Alciati MH: Performance and reporting
of clinical breast examination: a review of the literature.  CA
Cancer J Clin 2004, 54:345-361.
5. Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL,
Porter P, Hu YW, Zhao GL, Pan LD, et al.: Randomized trial of
breast self-examination in Shanghai: final results.  J Natl Can-
cer Inst 2002, 94:1445-1457.
6. Montemurro F, Martincich L, Sarotto I, Bertotto I, Ponzone R, Cel-
lini L, Redana S, Sismondi P, Aglietta M, Regge D: Relationship
between DCE-MRI morphological and functional features and
histopathological characteristics of breast cancer.  Eur Radiol
2007, 17:1490-1497.
7. Sloka JS, Hollett PD, Mathews M: A quantitative review of the
use of FDG-PET in the axillary staging of breast cancer.  Med
Sci Monit 2007, 13:RA37-RA46.
8. Pogue BW, Willscher C, McBride TO, Osterberg UL, Paulsen KD:
Contrast-detail analysis for detection and characterization
with near-infrared diffuse tomography.  Med Phys 2000,
27:2693-2700.
9. Tromberg BJ, Shah N, Lanning R, Cerussi A, Espinoza J, Pham T,
Svaasand L, Butler J: Non-invasive in vivo characterization of
breast tumors using photon migration spectroscopy.  Neopla-
sia 2000, 2:26-40.
10. Xu RX, Povoski SP: Diffuse optical imaging and spectroscopy
for cancer.  Expert Rev Med Devices 2007, 4:83-95.
11. Ntziachristos V, Chance B: Probing physiology and molecular
function using optical imaging: applications to breast cancer.
Breast Cancer Res 2001, 3:41-46.
12. Folkman J: What is the evidence that tumors are angiogenesis
dependent.  J Natl Cancer Inst 1990, 82:4-6.
13. Zhou S, Chen Y, Nioka Q, Li X, Pfaff L, Cowan CM, Chance B: A
portable dual wavelength amplitude cancellation image sys-
tem for the determination of human breast tumor.  Proc SPIE
1999, 3597:571-579.
14. Vaupel P, Schlenger K, Knoop C, Hockel M: Oxygenation of
human tumors: evaluation of tissue oxygen distribution in
bresat cancers by computerized O2 tension measurements.
Cancer Res 1991, 51:3316-3322.
15. Vaupel P: The role of hypoxia-induced factors in tumor
progression.  Oncologist 2004, 9(Suppl 5):10-17.
16. Vaupel P, Kelleher DK, Thews O: Modulation of tumor
oxygenation.  Int J Radiat Oncol Biol Phys 1998, 42:843-848.
17. McDonald DM, Baluk P: Significance of blood vessel leakiness
in cancer.  Cancer Res 2002, 62:5381-5385.
18. Boucher Y, Leunig M, Jain RK: Tumor angiogenesis and intersti-
tial hypertension.  Cancer Res 1996, 56:4264-4266.
19. Hockel M, Vaupel P: Tumor hypoxia: definitions and current
clinical, biologic, and molecular aspects.  J Natl Cancer Inst
2001, 93:266-276.
20. Chance B, Nioka S, Zhang J, Conant EF, Hwang E, Briest S, Orel
SG, Schnall MD, Czerniecki BJ: Breast cancer detection based
on incremental biochemical and physiological properties of
breast cancers: a six-year, two-site study.  Acad Radiol 2005,
12:925-933.
21. Srinivasan S, Pogue BW, Jiang S, Dehghani H, Kogel C, Soho S,
Gibson JJ, Tosteson TD, Poplack SP, Paulsen KD: Interpreting
hemoglobin and water concentration, oxygen saturation, and
scattering measured in vivo by near-infrared breast
tomography.  Proc Natl Acad Sci USA 2003, 100:12349-12354.
22. Shah N, Cerussi A, Eker C, Espinoza J, Butler J, Fishkin J, Hornung
R, Tromberg B: Noninvasive functional optical spectroscopy of
human breast tissue.  Proc Natl Acad Sci USA 2001,
98:4420-4425.
23. Shah N, Cerussi AE, Jakubowski D, Hsiang D, Butler J, Tromberg
BJ: The role of diffuse optical spectroscopy in the clinical man-
agement of breast cancer.  Dis Markers 2003, 19:95-105.
24. Shah N, Cerussi AE, Jakubowski D, Hsiang D, Butler J, Tromberg
BJ: Spatial variations in optical and physiological properties of
healthy breast tissue.  J Biomed Opt 2004, 9:534-540.
25. Pogue BW, Jiang S, Dehghani H, Kogel C, Soho S, Srinivasan S,
Song X, Tosteson TD, Poplack SP, Paulsen KD: Characterization
of hemoglobin, water, and NIR scattering in breast tissue:
analysis of intersubject variability and menstrual cycle
changes.  J Biomed Opt 2004, 9:541-552.
26. Srinivasan S, Pogue BW, Jiang S, Dehghani H, Kogel C, Soho S,
Gibson JJ, Tosteson TD, Poplack SP, Paulsen KD: In vivo hemo-
globin and water concentrations, oxygen saturation, and scat-
tering estimates from near-infrared breast tomography using
spectral reconstruction.  Acad Radiol 2006, 13:195-202.
27. Gu Y, Bourke VA, Kim JG, Constantinescu A, Mason RP, Liu H:
Dynamic response of breast tumor oxygenation to hyperoxic
respiratory challenge monitored with three oxygen-sensitive
parameters.  Appl Opt 2003, 42:2960-2967.
28. Schmitz CH, Klemer DP, Hardin R, Katz MS, Pei Y, Graber HL,
Levin MB, Levina RD, Franco NA, Solomon WB, Barbour RL:
Design and implementation of dynamic near-infrared optical
tomographic imaging instrumentation for simultaneous dual-
breast measurements.  Appl Opt 2005, 44:2140-2153.Breast Cancer Research    Vol 9 No 6    Xu et al.
Page 12 of 12
(page number not for citation purposes)
29. Cheng X, Xu X: Study of the pressure effect in near infrared
spectroscopy.  Proc SPIE 2003, 4955:397-406.
30. Jiang S, Pogue BW, Paulsen KD, Kogel C, Poplack S: In vivo
near-infrared spectral detection of pressure-induced changes
in breast tissue.  Opt Lett 2003, 28:1212-1214.
31. Xu R, Qiang B, Olsen J, Povoski S, Yee L, Mao J: Localization and
functional parameter reconstruction of suspicious breast
lesions by near infrared/ultrasound dual modal imaging.  Conf
Proc IEEE Eng Med Biol Soc 2005, 5:4473-4476.
32. Xu RX, Povoski SP, Yee LD, Olsen JO, Qiang B, Mao JM: Near
infrared/ultrasound dual modal imaging for breast cancer
detection.  Proc SPIE 2006, 6081:44-53.
33. Darling AL, Yalavarthy PK, Doyley MM, Dehghani H, Pogue BW:
Interstitial fluid pressure in soft tissue as a result of an exter-
nally applied contact pressure.  Phys Med Biol 2007,
52:4121-4136.
34. Xu RX, Qiang B, Mao JJ, Povoski SP: Development of a hand-
held near infrared imager for dynamic characterization of in
vivo biological tissue systems.  Appl Opt 2007, 46:7442-7451.
35. Chance B, Luo Q, Nioka S, Alsop DC, Detre JA: Optical investi-
gations of physiology: a study of intrinsic and extrinsic bio-
medical contrast.  Philos Trans R Soc Lond B Biol Sci 1997,
352:707-716.
36. Intes X, Ripoll J, Chen Y, Nioka S, Yodh AG, Chance B: In vivo
continuous-wave optical breast imaging enhanced with indo-
cyanine green.  Med Phys 2003, 30:1039-1047.
37. Intes X: Time-domain optical mammography SoftScan: initial
results.  Acad Radiol 2005, 12:934-947.
38. Svensson T, Swartling J, Taroni P, Torricelli A, Lindblom P, Ingvar
C, Andersson-Engels S: Characterization of normal breast tis-
sue heterogeneity using time-resolved near-infrared
spectroscopy.  Phys Med Biol 2005, 50:2559-2571.
39. Fantini S, Fanceschini MA, Maier JS, Walker SA, Barbieri B, Grat-
ton E: Frequency-domain multichannel optical detector for
non-invasive tissue spectroscopy and oximetry.  Opt Eng
1995, 34:32-42.
40. Ntziachristos V, Yodh AG, Schnall MD, Chance B: MRI-guided
diffuse optical spectroscopy of malignant and benign breast
lesions.  Neoplasia 2002, 4:347-354.
41. Zhu Q, Conant E, Chance B: Optical imaging as an adjunct to
sonograph in differentiating benign from malignant breast
lesions.  J Biomed Opt 2000, 5:229-236.
42. Cheng X, Mao J-m, Bush R, Kopans DB, Moore RH, Chorlton M:
Breast cancer detection by mapping hemoglobin concentra-
tion and oxygen saturation.  Appl Optics 2003, 42:6412-6421.
43. Kohl M, Nolte C, Heekeren HR, Horst S, Scholz U, Obrig H,
Villringer A: Determination of the wavelength dependence of
the differential pathlength factor from near-infrared pulse
signals.  Phys Med Biol 1998, 43:1771-1782.